A Phase 2 interventional study of MTBVAC and BCG in Tuberculosis, sponsored by Biofabri, S.L. Completed at 1 site in South Africa. Open to participants aged Up to 96 Hours, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Biofabri, S.L · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 210 studies in Tuberculosis with a site in South Africa — 21 open to participants now, 35 under way, 8 of them phase 3. Tuberculosis · South Africa.
Among the 210 studies in Tuberculosis with a site in South Africa, this one is the 112th largest by enrollment of the 176 interventional ones that give a count, is one of 21 that started in 2019, is one of 67 in phase 2, and was the 119th registered.
1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.
Browse Tuberculosis studies →21 of the 210 studies in Tuberculosis with a site in South Africa are open now. Recruiting first, the newest first:
University College, London · Sites in South Africa, Pakistan, Zimbabwe
Ages 16+
North-West University, South Africa · Sites in South Africa
Ages 18–45
Global Alliance for TB Drug Development · Sites in South Africa, Tanzania
Ages 18–65
TASK Applied Science · Sites in South Africa
Ages 18–65
Johns Hopkins University · Sites in South Africa, India, Indonesia and 4 more countries
Ages 0 days–9 yrs
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.
This study: Up to 96 Hours · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
210 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 86 · Phase 3 30 · Phase 4 9
First in 2000; this study’s year is marked. 21 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is below the median of 150 across 820 interventional studies indexed under Tuberculosis.
Median enrollment 214 across the 176 interventional studies, 770 across the 34 observational. Of the 161 that completed or were terminated, 64 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 210 have an industry lead sponsor. The 10 most frequent:
Biofabri, S.L is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Biofabri, S.L has 4 studies filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Tuberculosis with a site in South Africa that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06253715Phase 3Johns Hopkins UniversityShortened Regimen for Drug-susceptible TB in Children | 2027-09-30 |
| NCT06050356Statens Serum InstitutFirst-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b | 2026-12 |
| NCT03851159University of StellenboschNyaditum Resae® as a Co-adjuvant During Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota | 2026-12-31 |
| NCT05842161Massachusetts General HospitalSouth Africa Smoking Cessation and Engagement in HIV/TB Care Care | 2027-05-01 |
| NCT07672405Global Alliance for TB Drug DevelopmentSorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB | 2027-05-28 |
Add all 9 to your calendar (.ics) → With an account.
Among the 210 studies in Tuberculosis with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2a dose-defining study of MTBVAC to evaluate the safety, reactogenicity, immunogenicity, and potential for IGRA conversion and reversion, of MTBVAC in South African newborns. Ninety-nine HIV unexposed, BCG naïve newborns will be randomized to receive either BCG 2.5 x 105 CFU (n=24) or MTBVAC at one of three dose levels (n=75). Allocation will be double blind. Enrolment will be sequential into 3 cohorts of increasing MTBVAC dose (Cohort 1: n=25 MTBVAC 2.5 x 10E+04 and n=8 BCG; Cohort 2: n=25 MTBVAC 2.5 x 10E+05 and n=8 BCG; Cohort 3: n=25 MTBVAC 2.5 x 10E+06 and n=8 BCG). Dose escalation will be staggered to allow gradual evaluation of safety; final selection of the dose for Cohort 3 will be based on all available safety and immunogenicity data.
new effective tuberculosis (TB) vaccine is essential to achieve World Health Organization (WHO) End TB goals and eliminate TB by 2050. The optimal long-term strategy would be a combination of serial mass campaigns in adults, coupled with universal newborn vaccination. Newborns are the only human population without prior mycobacterial exposure in TB endemic countries and as such, live attenuated mycobacterial vaccines may offer better protection to this naïve population compared to adults.
MTBVAC is a novel TB vaccine candidate generated by genetically attenuating an M. tuberculosis clinical isolate of the EuroAmerican lineage. MTBVAC is based on two independent, stable genetic deletions of the genes coding for two major virulence factors, phoP coding for the transcription factor PhoP and fadD26 coding for the synthesis of PDIM. Since MTBVAC contains most of the genes deleted from BCG, it presents a wider collection of mycobacterial antigens to the host immune system. Safety and immunogenicity of MTBVAC has been demonstrated in BCG naive adults; and MTBVAC appears safe in a small ongoing Phase 1b study in South African newborns. Definitive demonstration of safety and immunogenicity at the optimal MTBVAC dose is key to progression into multi-centre efficacy trials in newborns.
A Phase 2a dose-defining study of MTBVAC to evaluate the safety, reactogenicity, immunogenicity, and potential for IGRA conversion and reversion, of MTBVAC in South African newborns. Ninety-nine HIV unexposed, BCG naïve newborns will be randomized to receive either BCG 2.5 x 105 CFU (n=24) or MTBVAC at one of three dose levels (n=75). Allocation will be double blind. Enrolment will be sequential into 3 cohorts of increasing MTBVAC dose (Cohort 1: n=25 MTBVAC 2.5 x 10E+04 and n=8 BCG; Cohort 2: n=25 MTBVAC 2.5 x 10E+05 and n=8 BCG; Cohort 3: n=25 MTBVAC 2.5 x 10E+06 and n=8 BCG). Dose escalation will be staggered to allow gradual evaluation of safety; final selection of the dose for Cohort 3 will be based on all available safety and immunogenicity data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria of Newborns:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MTBVAC intermediate dose 2.5 x 10E+04 CFU/0.05 mL
Biological: MTBVAC
MTBVAC high dose 2.5 x 10E+05 CFU/0.05 mL
Biological: MTBVAC
MTBVAC highest dose 2.5 x 10E+06 CFU/0.05 mL
Biological: MTBVAC
BCG control 2.5 x 10E+05 CFU/0.05 mL
Biological: BCG
Live-attenuated Mycobacterium tuberculosis based on the deletion of phoP and fadD26 virulence genes
Live-attenuated Mycobacterium bovis obtained by subculture passaging in ox-bile and glycerated potatoes between 1908-1921 by Albert Calmette and Camille Guerin. BCG is the only licensed vaccine today against tuberculosis (TB) mainly used in TB-endemic countries.
Also known as: Licensed BCG
Number of participants with treatment-related adverse events as defined in protocol.
* Solicited systemic adverse events: fever, irritability, vomiting, diarrhea, drowsiness, poor feeding, skin rash. * Solicited injection site reaction adverse events: pain, redness, swelling, ulceration, drainage, and regional lymphadenopathy * Unsolicited adverse events and serious adverse events
Time frame: 365 days post-vaccination
Immunogenicity analysis in infants
Measure of CD4 and CD8 T cells expressing specific cytokines in whole blood.
Time frame: 365 days post-vaccination
MTBVAC-induced QFT conversion and reversion kinetics
Quantitative and qualitative results of the QFT Gold Plus assay up to day 365 post-vaccination.
Time frame: 365 days post-vaccination
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2019 to primary completion in May 2022, 39 months.
Of 63 phase 2 interventional studies under Tuberculosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 36. This study's 39 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mtbvac
Biofabri, S.L